Clinical trials: Asthma, Bronchial
Asthma
Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma
This study is as an extension study of SD-004-0765, to assess the safety profile of long-term use of budesonide inhalation suspension in Japanese young children with bronchial asthma.
- Trial name
- NCT00232648
- Testing
- Pulmicort (budesonide) Respules
- Where
- 9 sites in Japan
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Asthma
Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbohaler in terms of the drug absorbed into the bloodstream.
- Trial name
- KINECO (NCT00964535)
- Testing
- budesonide and formoterol 200/6 microg
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- Orion Corporation, Orion Pharma
Healthy Volunteers, Asthma
A First Time in Human Study of PIN201104 in Healthy Volunteers and Patients With Asthma
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of different single and repeat doses of PIN201104 in healthy volunteers and in patients with asthma.
- Trial name
- NCT03058458
- Testing
- PIN201104
- Where
- United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Peptinnovate
Allergic Asthma
Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma
The primary purpose is to evaluate the safety and efficacy of recombinant humanized anti-IgE monoclonal antibody injection in patients with allergic asthma.
- Trial name
- AA007 (NCT01976208)
- Testing
- Omalizumab
- Where
- 27 sites in China
- Volunteers
- 630 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Asthma
Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers
Budesonide + Procaterol HFA MDI is a novel asthma product containing both budesonide and procaterol in a single inhaler. Budesonide is a corticosteroid that treats underlying airway inflammation in asthma.
- Trial name
- NCT02165033
- Testing
- Budesonide/Procaterol 180/10 X 4 puffs
- Where
- Taiwan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Intech Biopharm Ltd.
Asthma
Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)
Primary objective: The primary objective of the study was to compare the efficacy of Maintenance and Reliever Therapy (MART) with Foster® 100/6 μg (one inhalation bid) plus additional inhalations as needed, with the standard…
- Trial name
- NCT00861926
- Testing
- Salbutamol, Beclomethasone dipropionate + Formoterol
- Where
- 206 sites in Bulgaria, Croatia and 12 more
- Volunteers
- 1,714 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically…
- Trial name
- NIMBLE (NCT04718389)
- Testing
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab
- Where
- 397 sites in United States, Australia and 19 more
- Volunteers
- 1,717 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchoconstriction
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol
The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma
- Trial name
- NCT00685425
- Testing
- Levalbuterol HFA MDI, Racemic Albuterol
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Sumitomo Pharma America, Inc.
Allergy, Asthma
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
To demonstrate superiority of ALK HDM tablets versus placebo in immune response, measured as change of D.farinae specific immunoglobulin G4 (IgG4) from baseline to end of treatment with ALK HDM tablets given once daily over 60…
- Conditions
- Allergy, Asthma, Rhinitis
- Trial name
- NCT02596321
- Testing
- Mitizax
- Where
- 9 sites in Belarus, Russia
- Volunteers
- 112 people
- Sponsor
- Abbott
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Bronchial Asthma
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy
The purpose of the investigation is to confirm the safety of patients receiving Symbicort Turbuhaler as maintenance and reliever therapy ( Symbicort SMART) under the post-marketing actual use.
- Trial name
- NCT01711840
- Where
- 47 sites in Japan
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device
Phase IIa, single-centre, open-label, single-arm study, to evaluate the inspiration profile through the NEXThaler® device in adult asthmatic patients with varying degrees of disease control.
- Trial name
- NEXThalerPIF (NCT01651650)
- Testing
- Inhalation through Chiesi NEXThaler DPI
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma
This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma.
- Trial name
- NCT00605306
- Testing
- indacaterol maleate / mometasone furoate
- Where
- 3 sites in France
- Volunteers
- 28 people
- Sponsor
- Novartis
Asthma
To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma
This study is designed to assess the proportion of asthma subjects making critical and non-critical errors made in using ELLIPTA® inhaler compared with other commercially available inhaler devices such as the TURBUHALER®, MDI…
- Trial name
- NCT02195284
- Testing
- ELLIPTA, DISKUS/ACCUHALER, MDI
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 162 people
- Sponsor
- GlaxoSmithKline
Asthma
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
The objective of this study is to evaluate fluticasone furoate/vilanterol compared with fluticasone furoate alone in subjects with asthma that is uncontrolled on low to mid dose inhaled corticosteroid (ICS) or low dose ICS/ long…
- Trial name
- NCT03363191
- Testing
- Fluticasone Furoate/Vilanterol, Fluticasone Furoate, Salbutamol/Albuterol
- Sponsor
- GlaxoSmithKline
Asthma
GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects
GSK2190915 is currently in development for the treatment of asthma. This study aims to assess the safety and tolerability of single doses of GSK2190915 in healthy Japanese subjects.
- Trial name
- NCT00955383
- Testing
- GSK2190915
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma and Rhinitis
Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958
This study will evaluate the duration of effect of GSK2245035 on allergic reactivity by repeating a nasal allergen challenge (NAC) approximately one year after treatment in subjects from TL7116958.
- Trial name
- NCT02446613
- Testing
- Pollen allergen extract
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Allergy
Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus
Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the biovariability, differences in extraction process and subsequent handling of…
- Trial name
- NCT01147159
- Testing
- Extracts of allergens
- Where
- Switzerland
- Volunteers
- 68 people
- Sponsor
- Roxall Medicina España S.A
Asthma
Bioequivalence Study of Montelukast 10 mg Tablets
The objective of this study was to confirm if two formulations of montelukast tablets are bioequivalent. Test product was Montelukast (10 mg tablets; GlaxoSmithKline) and reference product Singulair (10 mg tablets; Merck Sharp \&…
- Trial name
- NCT01943942
- Testing
- Montelukast 10 mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.